Labeler · US market

Rising Pharmaceuticals, Inc

Rising Pharmaceuticals, Inc is a US drug labeler with US FDA registrations covering 1 drug concept (1 currently active) across 3 packages.

ACTIVE — US

openFDA · updated weekly

Labeler codes16571

Active drugs1

Registrations1 active / 1

Packages3

Sole supplier of0 drugs

Portfolio1 drugs · US

Every drug concept this labeler has US registrations for, by package count.

Drug	Type	NDCs	Packages	Status
Loratadine tablet	rx	1	3	SUPPLYING

At a glance

TypeLabeler
Labeler codes16571
Filing names1
Drugs (active)1
Drugs (all time)1
US registrations1
Packages3

Recent events

Shortages, recalls, and registration changes across all filing names.

Feb 15, 2023
RECALLRecall (Class II): Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 0766…
Feb 7, 2022
RECALLRecall (Class II): Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharmaceuti…
Sep 2, 2021
RECALLRecall (Class II): Meclizine HCl Tablets, 25 mg, packaged in 100-count HDPE bottle, Distributed by: Rising Pharma Holdings, Inc. East Brun…
Nov 15, 2019
RECALLRecall (Class III): Timolol Maleate Sterile Opthalmic Solution,USP 0.25%, 5 mL, Rx Only, For Topical Application, Distributed by: Rising Ph…
Nov 15, 2019
RECALLRecall (Class III): Timolol Maleate USP, 0.5%, 5 mL, Sterile Opthalmic Solution, Rx Only, For Topical Application in the Eye, Distributed…
Mar 7, 2019
RECALLRecall (Class II): Valsartan Tablets 160 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, …
Mar 7, 2019
RECALLRecall (Class II): Valsartan Tablets 80 mg USP, 90 tablet bottles, Rx only, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, …
Mar 7, 2019
RECALLRecall (Class II): Valsartan Tablets 320 mg USP, 90 tablet bottles, Distributed by: Acetris Health, LLC, Saddle Brook, NJ 07663, Manufactu…

Watch this company

Alerts for recalls, exits, and new registrations.

Facility locations, FDA inspections, and parent-company mapping are on the roadmap. Name variants reported to FDA under different spellings are merged into this profile; figures cover the entity across all its filing names.